Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail

Xenobiotica

Volumn 40, Issue 4, 2010, Pages 245-254

  Sevior, D K ^a   Hokkanen, J ^b   Tolonen, A ^b   Abass, K ^c   Tursas, L ^c   Pelkonen, O ^c   Ahokas, J T ^a  

^a RMIT UNIVERSITY   (Australia)

^b Novamass Analytical Ltd   (Finland)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

Complementary products; Herbdrug interactions; N in one cocktail

Indexed keywords

AESCULUS HIPPOCASTANUM EXTRACT; ANGELICA SINENSIS EXTRACT; CENTELLA ASIATICA EXTRACT; CIMICIFUGA RACEMOSA EXTRACT; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; EQUISETUM ARVENSE EXTRACT; GLYCYRRHIZA GLABRA EXTRACT; HERBACEOUS AGENT; HYDRASTIS CANADENSIS EXTRACT; METHANOL; PLANT EXTRACT; SABAL EXTRACT; SILYBUM MARIANUM EXTRACT; UNCLASSIFIED DRUG; VALERIAN;

AESCULUS HIPPOCASTANUM; ANGELICA POLYMORPHA; AQUEOUS SOLUTION; ARTICLE; CENTALLA ASIATICA; CIMICIFUGA RACEMOSA; CONTROLLED STUDY; DRUG MONITORING; DRUG SCREENING; ENZYME INHIBITION; ENZYME SUBSTRATE; EQUISETUM; EQUISETUM ARVENSE; FEMALE; GLYCYRRHIZA GLABRA; HERB DRUG INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDRASTIS; IC 50; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MEDICINAL PLANT; SABAL; SILYBUM MARIANUM; TANDEM MASS SPECTROMETRY; VALERIANA OFFICINALIS;

ARYL HYDROCARBON HYDROXYLASES; CENTELLA; CIMICIFUGA; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUGS, CHINESE HERBAL; ENZYME INHIBITORS; EQUISETUM; HUMANS; HYDRASTIS; METABOLIC DETOXICATION, DRUG; METHANOL; MICROSOMES, LIVER; PLACENTAL LACTOGEN; PLANT EXTRACTS; PLANT PREPARATIONS; TANDEM MASS SPECTROMETRY; WATER;

ANGELICA SINENSIS; CENTELLA ASIATICA; CIMICIFUGA DAHURICA; EQUISETALES; HYDRASTIS CANADENSIS;

EID: 77949457681     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498251003592683     Document Type: Article

References (33)

1. Barnes P, Bloom B, Nahin R. (2008). Complementary and alternative medicine se among adults and children: United States, 2007. National Health Statistics Report. Washington, DC: US Department of Health and Human Services.
2. Bradford M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt Biochem. 72:248-254
3. Budzinski JW, Foster B, Vandenhoek S, Arnason J. (2000). An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine. 7:273-282
4. Chatterjee P, Franklin M. (2003). Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Disposit. 31:1391-1397
5. Eisenberg DM, Davis RB, Ettner SL. (1998). Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. J Am Med Assoc. 280:1569-1575
6. Foster B, Vandenhoek S, Hana J, Krantis A, Akhtar M, Bryan M, Budzinski J, Ramputh A, Arnason J. (2003). In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine. 10:334-342
7. Gurley B, Gardner S, Hubbard M, Williams D, Gentry W, Carrier J, Khan I, Edwards D, Shah A. (2004). In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Pharmacokinet Drug Disposit. 76:428-440
8. Gurley B, Gardner S, Hubbard M, Williams K, Gentry W, Khan I, Shah A. (2005). In vivo effects of goldenseal, kava kava, black cohosh and valerian on human cytochrome P450 1A2, 2D6, 2E1 and 3A4 phenotypes. Clin Pharmacol Ther. 77:415-426
9. Gurley B, Hubbard M, Williams D, Thaden J, Tong Y, Gentry W, Breen P, Carrier D, Cheboyina S. (2006). Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: Comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol. 46:201-213
10. Gurley B, Swain A, Hubbard M, Williams D, Varone G, Hartsfield F, Tong Y, Carrier D, Cheboyina S, Battu S (2008). Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort and Echinacea. Mol Nutr Food Res. 52:1-9.
11. Hellum B, Nilsen O. (2008). In vitro inhibition of CYP3A4 metabolism and P-glycoprotein mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol. 102:466-475
12. Kay L, Kampmann J, Svendsen T, Vergman B, Hansen J, Skovsted L, Kristensen M. (1985). Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol. 20:323-326
13. Kent U, Aviram M, Rosenblat M, Hollenberg P. (2002). The licorice root derived isoflavin glabridin inhibits the activities of human cytochrome P450s 3A4, 2B6 and 2C9. Drug Metab Disposit. 30:709-715
14. Lee L, Andrade A, Flexner C. (2006). Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. Clin Infect Dis. 43:1052-1059
15. Lefebvre T, Foster B. (2004). In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharmacol Pharmaceut Sci. 7:265-273
16. Markowitz J, Donovan J, DeVane C, Taylor R, Ruan Y, Wang J, Chavin K. (2003). Multiple doses of saw palmetto (Serona repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther. 74:536-542
17. Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsottir G, Hummerston S, Ahmad AM, Platin N, Kearney N, Patiraki E. (2005). Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 16:655-663
18. Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ. (1981). Diazepam interaction with antituberculosis drugs. Clin Pharmacol Ther. 29:671-678
19. Pelkonen OP, Kaltiala EH, Larmi TK. I, Karki NT. (1974). Cytochrome P450-linked monooxygenase system and drug-induced spectral interactions in human liver microsomes. Chemico-Biol Interact. 9:205-216
20. Scott I, Leduc R, Burt A, Marles R, Arnason J, Foster B. (2006). The inhibition of human cytochrome P450 by ethanol extracts of North American botanicals. Pharmaceut Biol. 44:315-327
21. Strandell J, Neil A, Carlin G. (2004). An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine. 11:98-104.
22. Tang J, Zhang J, Wu Y, Li Z. (2006). Effect of the water extract and ethanol extract from traditional Chinese medicines Angelica sinensis (oliv) diels, Ligusticum chuanxiong Hort. and Rheum palmatum L. on rat liver cytochrome P450 activity. Phytother Res. 20:1046-1051
23. Thomas KJ, Nicholl JP, Coleman P. (2001). Use and expenditure on complementary medicine in England: a population based survey. Complement Ther Med. 9:2-11.
24. Tolonen A, Petsalo A, Turpeinen M, Uusitalo J, Pelkonen O. (2007). In vitro interaction cocktail for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MS-MS run: analytical validation and testing with monoclonal anti-CYP antibodies. J Mass Spectrom. 42:960-966
25. Turpeinen M, Ghiciuc C, Opritoui M, Tursas L, Pelkonen OP, Pasanen M. (2007). Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro. Xenobiotica. 37: 1367-1377
26. Turpeinen M, Korhonen L, Tolonen A, Uusitalo J, Juvonen R, Raunio H, Pelkonen OP. (2006). Cytochrome P450 (CYP) inhibition screening: comparison of three tests. Eur J Pharmaceut Sci. 29:130-138
27. Turpeinen M, Uusitalo J, Jalonen J, Pelkonen OP. (2005). Multiple P450 substrates in a single run: Rapid and comprehensive in vitro interaction assay. Eur J Pharmaceut Sci. 24:123-132
28. Unger M, Frank A. (2004). Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Comm Mass Spectrom. 18:2273-2281
29. Williams J, Hyland R, Jones B, Smith D, Hurst S, Goosen T, Peterkin V, Koup J, Ball S. (2004). Drug-drug interactions for UDPglucuronsyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCl/AUC) ratios. Drug Metab Disposit. 32:1201-1208
30. World Health Organization (WHO). (2008). Traditional medicine. Geneva: WHO.
31. Xie H, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, Rane A. (2003). Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomic J. 3:53-61.
32. Xue CC, Zhang A, Kin V, Da Costa C, Story D. (2007). Complementary and alternative medicine use in Australia: a national populationbased survey. J Alt Complement Med. 13:643-650
33. Yoo H, Lee M, Kim Y, Yun C, Kim D. (2007). Mechanism-based inactivation of cytochrome P450 2A6 by decursinol angelate isolated from Angelica gigas. Drug Metab Disposit. 35:1759-1765